Bioadhesive Propanediol Composition for Mucosal Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory conditions in mucous membranes and skin, such as those caused by cytokines like TNF-α and IL-2, often require high concentrations of propylene glycol, which can cause adverse effects, and there is a need for effective, low-concentration alternatives.
Innovation Solution
A pharmaceutical composition comprising 0.001 to 2% propane-1,2-diol and a bioadhesive polymer for local application, which significantly reduces TNF-α and IL-2 without the adverse effects associated with higher concentrations of propylene glycol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of propylene glycol are used to treat inflammatory conditions, then the treatment effectiveness is improved, but adverse effects such as dehydration and toxicity increase
Solution Approach 1:
The patent changes the concentration parameter of propylene glycol from high (conventional) to low (0.001-2%), and compensates by changing the molecular structure parameter by using propane-1,2-diol isomers (specifically 1,2-propanediol and/or 1,3-propanediol) which exhibit different biological activities at low concentrations, thereby maintaining treatment effectiveness while reducing adverse effects
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining low concentrations of propane-1,2-diol with other ingredients (such as water, buffers, and excipients) to achieve synergistic effects that provide anti-inflammatory activity without the toxicity associated with high concentrations of conventional propylene glycol
2Reliability
If high concentrations of propylene glycol are used to reduce cytokines, then the anti-inflammatory effect is improved, but the risk of toxicity increases
Solution Approach 1:
The patent changes the concentration parameter to low levels (0.001-2%) and changes the chemical structure parameter by using specific propane-1,2-diol isomers that possess inherent anti-inflammatory properties through alternative mechanisms, thereby achieving cytokine reduction without toxic effects
Solution Approach 2:
The patent employs a formulation strategy where low concentrations of the active ingredient are used locally at the site of application, providing sufficient therapeutic effect without systemic absorption that could lead to toxicity, effectively treating the condition with minimal harmful exposure
3Adaptability or versatility
If conventional treatments are used for inflammatory conditions, then the treatment coverage is improved, but the side effects such as dehydration increase
Solution Approach 1:
The patent changes the concentration parameter of the active ingredient and the chemical composition parameters by using propane-1,2-diol isomers with different hygroscopic properties compared to conventional propylene glycol, thereby maintaining broad treatment coverage for various inflammatory conditions without causing dehydration
Solution Approach 2:
The patent applies the pharmaceutical composition locally at the site of inflammatory conditions (mucous membranes and skin), where the low concentration of propane-1,2-diol provides targeted anti-inflammatory effect without affecting the overall hydration status of the body, thus avoiding systemic dehydration side effects
Data Source
AI summary
The invention relates a pharmaceutical composition comprising from 0.001 to 2% (w/v) of propane-1,2-diol as the only anti-inflammatory agent and at least one bioadhesive polymer. The pharmaceutical composition can be used in amelioration, prevention or treatment of an inflammatory condition in a mucous membrane or skin of a subject, and/or in treatment of pain associated with such an 5 inflammatory condition.